広島大学大学院医歯薬保健学研究科

消化器⋅代謝内科学

(広島大学病院 旧第一内科)

業績・活動

主要業績

主要業績

  • Shakado S, Sakisaka S, Okanoue T, Chayama K, Izumi N, Toyoda J, Tanaka E, Ido A, Takehara T, Yoshioka K, Hiasa Y, Nomura H, Seike M, Ueno Y, Kumada H. Interleukin 28B polymorphism predicts interferon plus ribavirin treatment outcome in patients with hepatitis C virus-related liver cirrhosis: A multicenter retrospective study in Japan. Hepatol Res. 2014; 44: 983-992.

  • Tanaka Y, Ohira M, Tashiro H, Imamura M, Chayama K, Ohdan H. Impact of alloimmune T cell responses on hepatitis C virus replication in liver transplant recipients. Hum Immunol. 2014; 75: 1259-1267.

  • Takahashi S, Kimura T, Kenjo M, Nishibuchi I, Takahashi I, Takeuchi Y, Doi Y, Kaneyasu Y, Murakami Y, Honda Y, Aikata H, Chayama K, Nagata Y. Case reports of portal vein thrombosis and bile duct stenosis after stereotactic body radiation therapy for hepatocellular carcinoma. Hepatol Res. 2014; 44: E273-278.

  • Miwata T, Hiyama T, Quach D, Le H, Hua H, Oka S, Tanaka S, Arihiro K, Chayama K. Differences in K- ras and mitochondrial DNA mutations and microsatellite instability between colorectal cancers of Vietnamese and Japanese patients. BMC Gastroenterol. 2014; 14: 203.

  • Shahidi M, Tay ES, Read SA, Ramezani-Moghadam M, Chayama K, George J, Douglas MW. Endocannabinoid CB1 antagonists inhibit hepatitis C virus production, providing a novel class of antiviral host-targeting agents. J Gen Virol. 2014; 95: 2468-2479.

  • Tanaka K, Hyogo H, Ono M, Takahashi H, Kitajima Y, Ono N, Eguchi T, Fujimoto K, Chayama K, Saibara T, Anzai K, Eguchi Y, Japan Study Group of Non-alcoholic Fatty Liver D. Upper limit of normal serum alanine aminotransferase levels in Japanese subjects. Hepatol Res. 2014; 44: 1196-1207.

  • Nakahara T, Hyogo H, Yoneda M, Sumida Y, Eguchi Y, Fujii H, Ono M, Kawaguchi T, Imajo K, Aikata H, Tanaka S, Kanemasa K, Fujimoto K, Anzai K, Saibara T, Sata M, Nakajima A, Itoh Y, Chayama K, Okanoue T, Japan Study Group of Nonalcoholic Fatty Liver D. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol. 2014; 49: 1477-1484.

  • Quach DT, Hiyama T, Shimamoto F, Le QD, Ho LX, Vu NH, Yoshihara M, Uemura N. Value of a new stick-type rapid urine test for the diagnosis of Helicobacter pylori infection in the Vietnamese population. World J Gastroenterol. 2014; 20: 5087-5091.

  • Yokoyama S, Takahashi S, Kawakami Y, Hayes CN, Kohno H, Kohno H, Tsuji K, Aisaka Y, Kira S, Yamashina K, Nonaka M, Moriya T, Kitamoto M, Aimitsu S, Nakanishi T, Kawakami H, Chayama K. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. J Viral Hepat. 2014; 21: 348-356.

  • Naeshiro N, Aikata H, Kakizawa H, Hyogo H, Kan H, Fujino H, Kobayashi T, Fukuhara T, Honda Y, Ohno A, Miyaki D, Kawaoka T, Tsuge M, Hiraga N, Hiramatsu A, Imamura M, Kawakami Y, Takahashi S, Awai K, Chayama K. Long-term outcome of patients with gastric varices treated by balloon-occluded retrograde transvenous obliteration. J Gastroenterol Hepatol. 2014; 29: 1035-1042.

  • Sato Y, Imamura H, Kaizaki Y, Koizumi W, Ishido K, Kurahara K, Suzuki H, Fujisaki J, Hirakawa K, Hosokawa O, Ito M, Kaminishi M, Furuta T, Chiba T, Haruma K. Management and clinical outcomes of type I gastric carcinoid patients: retrospective, multicenter study in Japan. Dig Endosc. 2014; 26: 377-384.

  • Fukuhara T, Hyogo H, Ochi H, Fujino H, Kan H, Naeshiro N, Honda Y, Miyaki D, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Chayama K. Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus. Hepatogastroenterology. 2014; 61: 323-328.

  • Kan H, Kimura Y, Hyogo H, Fukuhara T, Fujino H, Naeshiro N, Honda Y, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Ochi H, Arihiro K, Chayama K. Non-invasive assessment of liver steatosis in non-alcoholic fatty liver disease. Hepatol Res. 2014; 44: E420-427.

  • Fujiya K, Nagata N, Uchida T, Kobayakawa M, Asayama N, Akiyama J, Shimbo T, Igari T, Banerjee R, Nageshwar Reddy D, Mizokami M, Uemura N. Different gastric mucosa and CagA status of patients in India and Japan infected with Helicobacter pylori. Dig Dis Sci. 2014; 59: 631-637.

  • Kajikawa M, Maruhashi T, Iwamoto Y, Iwamoto A, Matsumoto T, Hidaka T, Kihara Y, Chayama K, Nakashima A, Goto C, Noma K, Higashi Y. Borderline ankle-brachial index value of 0.91-0.99 is associated with endothelial dysfunction. Circ J. 2014; 78: 1740-1745.

  • Ochi H, Miki D, Hayes CN, Abe H, Hayashida Y, Kubo M, Chayama K. IFNL4/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population. J Gen Virol. 2014; 95: 1297-1306.

  • Sanomura Y, Oka S, Tanaka S, Numata N, Higashiyama M, Kanao H, Yoshida S, Ueno Y, Chayama K. Continued use of low-dose aspirin does not increase the risk of bleeding during or after endoscopic submucosal dissection for early gastric cancer. Gastric Cancer. 2014; 17: 489-496.

  • Oka S, Tanaka S, Chayama K. Detection of nonpolypoid colorectal neoplasia using magnifying endoscopy in colonic inflammatory bowel disease. Gastrointest Endosc Clin N Am. 2014; 24: 405-417.

  • Taketani H, Sumida Y, Tanaka S, Imajo K, Yoneda M, Hyogo H, Ono M, Fujii H, Eguchi Y, Kanemasa K, Chayama K, Itoh Y, Yoshikawa T, Saibara T, Fujimoto K, Nakajima A, Japan Study Group of N. The association of insomnia with gastroesophageal reflux symptoms in biopsy-proven nonalcoholic fatty liver disease. J Gastroenterol. 2014; 49: 1163-1174.

  • Naeshiro N, Kakizawa H, Aikata H, Kan H, Fujino H, Fukuhara T, Kobayashi T, Honda Y, Miyaki D, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Hyogo H, Ishikawa M, Awai K, Chayama K. Percutaneous transvenous embolization for portosystemic shunts associated with encephalopathy: Long-term outcomes in 14 patients. Hepatol Res. 2014; 44: 740-749.

  • Honda Y, Kimura T, Aikata H, Nakahara T, Naeshiro N, Tanaka M, Miyaki D, Nagaoki Y, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Ishikawa M, Kakizawa H, Kenjo M, Awai K, Nagata Y, Chayama K. Pilot study of stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. Hepatogastroenterology. 2014; 6:1 31-36.

  • McPhee F, Hernandez D, Zhou N, Yu F, Ueland J, Monikowski A, Chayama K, Toyota J, Izumi N, Yokosuka O, Kawada N, Osaki Y, Hughes EA, Watanabe H, Ishikawa H, Kumada H. Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b. Antivir Ther. 2014; 19: 479-490.

  • Tanimine N, Tanaka Y, Kobayashi T, Tashiro H, Miki D, Imamura M, Aikata H, Tanaka J, Chayama K, Ohdan H. Quantitative effect of natural killer-cell licensing on hepatocellular carcinoma recurrence after curative hepatectomy. Cancer Immunol Res. 2014; 2: 1142-1147.

  • Fujino H, Imamura M, Nagaoki Y, Kawakami Y, Abe H, Hayes CN, Kan H, Fukuhara T, Kobayashi T, Masaki K, Ono A, Nakahara T, Honda Y, Naeshiro N, Urabe A, Yokoyama S, Miyaki D, Murakami E, Kawaoka T, Hiraga N, Tsuge M, Hiramatsu A, Hyogo H, Aikata H, Takahashi S, Miki D, Ochi H, Ohishi W, Chayama K, Hiroshima Liver Study G. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C. J Gastroenterol. 2014; 49: 1548-1556.

  • Kessoku T, Ogawa Y, Yoneda M, Imajo K, Sumida Y, Eguchi Y, Fujii H, Hyogo H, Ono M, Suzuki Y, Kawaguchi T, Chayama K, Tanaka S, Fujimoto K, Anzai K, Saibara T, Sata M, Itoh Y, Nakajima A, Okanoue T, Japan Study Group of N. Simple scoring system for predicting cirrhosis in nonalcoholic fatty liver disease. World J Gastroenterol. 2014; 20: 10108-10114.

  • Nagaoki Y, Imamura M, Kawakami Y, Kan H, Fujino H, Fukuhara T, Kobayashi T, Ono A, Nakahara T, Naeshiro N, Urabe A, Yokoyama S, Miyaki D, Murakami E, Kawaoka T, Tsuge M, Hiramatsu A, Aikata H, Takahashi S, Hayes CN, Ochi H, Chayama K, Hiroshima Liver Study G. Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C. Hepatol Res. 2014; 44: E447-454.

  • Oka S, Tanaka S, Nakadoi K, Asayama N, Chayama K. Endoscopic features and management of diminutive colorectal submucosal invasive carcinoma. Dig Endosc. 2014; 26: Suppl 2: 78-83.

  • Asayama N, Nagata N, Shimbo T, Nishimura S, Igari T, Akiyama J, Ohmagari N, Hamada Y, Nishijima T, Yazaki H, Teruya K, Oka S, Uemura N. Relationship between clinical factors and severity of esophageal candidiasis according to Kodsi's classification. Dis Esophagus. 2014; 27: 214-219.

  • Abe H, Hayes CN, Chayama K. New insight into the enhanced effect of pegylated interferon-alpha. Hepatology. 2014; 60: 1435-1437.

  • Kohno T, Tsuge M, Murakami E, Hiraga N, Abe H, Miki D, Imamura M, Ochi H, Hayes CN, Chayama K. Human microRNA hsa-miR-1231 suppresses hepatitis B virus replication by targeting core mRNA. J Viral Hepat. 2014; 21: e89-97.

  • Minami T, Sasaki T, Serikawa M, Ishigaki T, Murakami Y, Chayama K. Antibiotic prophylaxis for endoscopic retrograde chlangiopancreatography increases the detection rate of drug-resistant bacteria in bile. J Hepatobiliary Pancreat Sci. 2014; 21: 712-718.

  • Kitamura Y, Ito M, Matsuo T, Boda T, Oka S, Yoshihara M, Tanaka S, Chayama K. Characteristic epithelium with low-grade atypia appears on the surface of gastric cancer after successful Helicobacter pylori eradication therapy. Helicobacter. 2014; 19: 289-295.

  • Kagemoto K, Oka S, Tanaka S, Miwata T, Urabe Y, Sanomura Y, Yoshida S, Hiyama T, Arihiro K, Chayama K. Clinical outcomes of endoscopic submucosal dissection for superficial Barrett's adenocarcinoma. Gastrointest Endosc. 2014; 80: 239-245.

  • Kitamoto A, Kitamoto T, Nakamura T, Ogawa Y, Yoneda M, Hyogo H, Ochi H, Mizusawa S, Ueno T, Nakao K, Sekine A, Chayama K, Nakajima A, Hotta K. Association of polymorphisms in GCKR and TRIB1 with nonalcoholic fatty liver disease and metabolic syndrome traits. Endocr J. 2014; 6:1 683-689.

  • Terasaki M, Tanaka S, Shigita K, Asayama N, Nishiyama S, Hayashi N, Nakadoi K, Oka S, Chayama K. Risk factors for delayed bleeding after endoscopic submucosal dissection for colorectal neoplasms. Int J Colorectal Dis. 2014; 29: 877-882.

  • Maruhashi T, Nakashima A, Matsumoto T, Oda N, Iwamoto Y, Iwamoto A, Kajikawa M, Kihara Y, Chayama K, Goto C, Noma K, Higashi Y. Relationship between nitroglycerine-induced vasodilation and clinical severity of peripheral artery disease. Atherosclerosis. 2014; 235: 65-70.

  • Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, Izumi N, Koike K, Takehara T, Kawada N, Sata M, Miyagoshi H, Eley T, McPhee F, Damokosh A, Ishikawa H, Hughes E. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014; 59: 2083-2091.

  • Kitamoto T, Kitamoto A, Yoneda M, Hyogo H, Ochi H, Mizusawa S, Ueno T, Nakao K, Sekine A, Chayama K, Nakajima A, Hotta K. Targeted next-generation sequencing and fine linkage disequilibrium mapping reveals association of PNPLA3 and PARVB with the severity of nonalcoholic fatty liver disease. J Hum Genet. 2014; 59: 241-246.

  • Murakami E, Imamura M, Hayes CN, Abe H, Hiraga N, Honda Y, Ono A, Kosaka K, Kawaoka T, Tsuge M, Aikata H, Takahashi S, Miki D, Ochi H, Matsui H, Kanai A, Inaba T, McPhee F, Chayama K. Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin. Antimicrob Agents Chemother. 2014; 58: 2105-2112.

  • Kajikawa M, Noma K, Maruhashi T, Mikami S, Iwamoto Y, Iwamoto A, Matsumoto T, Hidaka T, Kihara Y, Chayama K, Nakashima A, Goto C, Liao JK, Higashi Y. Rho-associated kinase activity is a predictor of cardiovascular outcomes. Hypertension. 2014; 63: 856-864.

  • Nakadoi K, Oka S, Tanaka S, Hayashi N, Terasaki M, Arihiro K, Shimamoto F, Chayama K. Condition of muscularis mucosae is a risk factor for lymph node metastasis in T1 colorectal carcinoma. Surg Endosc. 2014; 28: 1269-1276.

  • Nishiyama S, Oka S, Tanaka S, Hayashi N, Hayashi R, Nagai K, Ueno Y, Shimamoto F, Arihiro K, Chayama K. Is it possible to discriminate between neoplastic and nonneoplastic lesions in ulcerative colitis by magnifying colonoscopy? Inflamm Bowel Dis. 2014; 20: 508-513.

  • Hayashi N, Tanaka S, Nishiyama S, Terasaki M, Nakadoi K, Oka S, Yoshihara M, Chayama K. Predictors of incomplete resection and perforation associated with endoscopic submucosal dissection for colorectal tumors. Gastrointest Endosc. 2014; 79: 427-435.

  • Ishigaki T, Sasaki T, Serikawa M, Minami T, Okazaki A, Yukutake M, Ishii Y, Kosaka K, Mouri T, Yoshimi S, Chayama K. Comparative study of 4 Fr versus 6 Fr nasobiliary drainage catheters: a randomized, controlled trial. J Gastroenterol Hepatol. 2014; 29: 653-659.

  • Aoyama T, Oka S, Aikata H, Nakano M, Watari I, Naeshiro N, Yoshida S, Tanaka S, Chayama K. Is small-bowel capsule endoscopy effective for diagnosis of esophagogastric lesions related to portal hypertension? J Gastroenterol Hepatol. 2014; 29: 511-516.

  • Ishikawa M, Yamagami T, Kakizawa H, Hieda M, Toyota N, Fukumoto W, Kajiwara K, Yoshimatsu R, Aikata H, Chayama K, Awai K. Transarterial therapy of hepatocellular carcinoma fed by the right renal capsular artery. J Vasc Interv Radiol. 2014; 25: 389-395.

  • Abe H, Kimura A, Tsuruta S, Fukaya T, Sakaguchi R, Morita R, Sekiya T, Shichita T, Chayama K, Fujii-Kuriyama Y, Yoshimura A. Aryl hydrocarbon receptor plays protective roles in ConA-induced hepatic injury by both suppressing IFN-gamma expression and inducing IL-22. Int Immunol. 2014; 26: 129-137.

  • Takaki S, Kawakami Y, Miyaki D, Nakahara T, Naeshiro N, Murakami E, Tanaka M, Honda Y, Yokoyama S, Nagaoki Y, Kawaoka T, Hiramatsu A, Tsuge M, Hiraga N, Imamura M, Hyogo H, Aikata H, Takahashi S, Arihiro K, Chayama K. Non-invasive liver fibrosis score calculated by combination of virtual touch tissue quantification and serum liver functional tests in chronic hepatitis C patients. Hepatol Res. 2014; 44: 280-287.

  • Takahashi Y, Ando M, Nishikawa M, Hiraga N, Imamura M, Chayama K, Takakura Y. Long-term elimination of hepatitis C virus from human hepatocyte chimeric mice after interferon-gamma gene transfer. Hum Gene Ther Clin Dev. 2014; 25: 28-39.

  • Kawaoka T, Aikata H, Kan H, Fujino H, Fukuhara T, Kobayashi T, Naeshiro N, Miyaki D, Hiramatsu A, Imamura M, Kawakami Y, Hyogo H, Chayama K. Clinical outcome and prognostic factors of patients with hepatocellular carcinoma and extrahepatic metastasis treated with sorafenib. Hepatol Res. 2014; 44: 1320-1328.

  • Kajikawa M, Nakashima A, Maruhashi T, Iwamoto Y, Iwamoto A, Matsumoto T, Hidaka T, Kihara Y, Chayama K, Goto C, Taguchi A, Noma K, Higashi Y. Poor oral health, that is, decreased frequency of tooth brushing, is associated with endothelial dysfunction. Circ J. 2014; 78: 950-954.

  • Boda T, Ito M, Yoshihara M, Kitamura Y, Matsuo T, Oka S, Tanaka S, Chayama K. Advanced method for evaluation of gastric cancer risk by serum markers: determination of true low-risk subjects for gastric neoplasm. Helicobacter. 2014; 19: 1-8.

  • Yokoyama S, Kawakami Y, Chayama K. Letter: Pitavastatin supplementation of PEG-IFN/ribavirin improves sustained virological response against HCV. Aliment Pharmacol Ther. 2014; 39: 443-444.

  • Hyogo H, Yamagishi S, Maeda S, Fukami K, Ueda S, Okuda S, Nakahara T, Kimura Y, Ishitobi T, Chayama K. Serum asymmetric dimethylarginine levels are independently associated with procollagen III N-terminal peptide in nonalcoholic fatty liver disease patients. Clin Exp Med 2014; 14: 45-51.

  • Oka S, Tanaka S, Higashiyama M, Numata N, Sanomura Y, Yoshida S, Arihiro K, Chayama K. Clinical validity of the expanded criteria for endoscopic resection of undifferentiated-type early gastric cancer based on long-term outcomes. Surg Endosc. 2014; 28: 639-647.

  • Suzuki F, Toyota J, Ikeda K, Chayama K, Mochida S, Hayashi N, Ishikawa H, Miyagoshi H, Hu W, McPhee F, Hughes EA, Kumada H. A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection. Antivir Ther. 2014; 19: 491-499.

  • Kawaoka T, Takahashi S, Tatsukawa Y, Hiramatsu A, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Aikata H, Ochi H, Ishiyama K, Ide K, Tashiro H, Ohdan H, Chayama K. Two patients treated with pegylated interferon/ribavirin/telaprevir triple therapy for recurrent hepatitis C after living donor liver transplantation. Hepatol Res. 2014; 44: 1259-1264.

  • Ohishi W, Cologne JB, Fujiwara S, Suzuki G, Hayashi T, Niwa Y, Akahoshi M, Ueda K, Tsuge M, Chayama K. Serum interleukin-6 associated with hepatocellular carcinoma risk: a nested case-control study. Int J Cancer. 2014; 134: 154-163.

  • Yukutake M, Sasaki T, Serikawa M, Minami T, Okazaki A, Ishigaki T, Ishii Y, Kosaka K, Mouri T, Yoshimi S, Shimizu A, Tsuboi T, Tanitame K, Chayama K. Timing of radiological improvement after steroid therapy in patients with autoimmune pancreatitis. Scand J Gastroenterol. 2014; 49: 727-733.

  • Yukutake M, Sasaki T, Serikawa M, Minami T, Okazaki A, Ishigaki T, Fujimoto Y, Hatta Y, Kitamura S, Chayama K. The effect of respiratory-gated positron emission tomography/computed tomography in patients with pancreatic cancer. Hell J Nucl Med. 2014; 17: 31-36.

  • Boda T, Ito M, Oka S, Kitamura Y, Numata N, Sanomura Y, Matsuo T, Tanaka S, Yoshihara M, Arihiro K, Chayama K. Characteristics of metachronous gastric tumors after endoscopic submucosal dissection for gastric intraepithelial neoplasms. Gastroenterol Res Pract. 2014; 2014: 863595.

  • Hyogo H, Chayama K, Yamagishi S. Nonalcoholic fatty liver disease and cardiovascular disease. Curr Pharm Des. 2014; 20: 2403-2411.

  • Sakuma T, Nishikawa A, Kume S, Chayama K, Yamamoto T. Multiplex genome engineering in human cells using all-in-one CRISPR/Cas9 vector system. Sci Rep. 2014; 4: 5400.

  • Watari I, Oka S, Tanaka S, Igawa A, Nakano M, Aoyama T, Yoshida S, Chayama K. Comparison of small-bowel mucosal injury between low-dose aspirin and non-aspirin non-steroidal anti-inflammatory drugs: a capsule endoscopy study. Digestion. 2014; 89: 225-231.

  • Kawakami Y, Suzuki F, Karino Y, Toyota J, Kumada H, Chayama K. Telaprevir is effective given every 12 h at 750 mg with pegylated interferon-alpha2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT. Antivir Ther. 2014; 19: 277-285.

  • Ishida M, Ishida T, Tashiro S, Uchida H, Sakai C, Hironobe N, Miura K, Hashimoto Y, Arihiro K, Chayama K, Kihara Y, Yoshizumi M. Smoking cessation reverses DNA double-strand breaks in human mononuclear cells. PLoS One. 2014; 9: e103993.

  • Maruhashi T, Noma K, Iwamoto Y, Iwamoto A, Oda N, Kajikawa M, Matsumoto T, Hidaka T, Kihara Y, Chayama K, Nakashima A, Goto C, Liao JK, Higashi Y. Critical role of exogenous nitric oxide in ROCK activity in vascular smooth muscle cells. PLoS One. 2014; 9: e109017.

  • Mori N, Imamura M, Takaki S, Araki T, Hayes NC, Aisaka Y, Chayama K. Hepatitis C virus (HCV) reactivation caused by steroid therapy for dermatomyositis. Intern Med. 201;4 53: 2689-2693.

  • Minami T, Sasaki T, Serikawa M, Kamigaki M, Yukutake M, Ishigaki T, Ishii Y, Mouri T, Yoshimi S, Shimizu A, Tsuboi T, Kurihara K, Tatsukawa Y, Miyaki E, Chayama K. Occupational Radiation Exposure during Endoscopic Retrograde Cholangiopancreatography and Usefulness of Radiation Protective Curtains. Gastroenterol Res Pract. 2014; 2014: 926876.

  • Shiraishi Y, Fujimoto A, Furuta M, Tanaka H, Chiba K, Boroevich KA, Abe T, Kawakami Y, Ueno M, Gotoh K, Ariizumi S, Shibuya T, Nakano K, Sasaki A, Maejima K, Kitada R, Hayami S, Shigekawa Y, Marubashi S, Yamada T, Kubo M, Ishikawa O, Aikata H, Arihiro K, Ohdan H, Yamamoto M, Yamaue H, Chayama K, Tsunoda T, Miyano S, Nakagawa H. Integrated analysis of whole genome and transcriptome sequencing reveals diverse transcriptomic aberrations driven by somatic genomic changes in liver cancers. PLoS One. 2014; 9: e114263.

  • Asayama N, Kojima Y, Aoki T, Maeyashiki C, Yokoi C, Yanase M, Suda R, Yano H, Nakamura H, Igari T. Acinar cell carcinoma of the pancreas with colon involvement. Case Rep Med. 2014; 2014: 389425.

  • Kobayashi M, Sako A, Ogami T, Nishimura S, Asayama N, Yada T, Nagata N, Sakurai T, Yokoi C, Kobayakawa M, Yanase M, Masaki N, Takeshita N, Uemura N. Validation of the 3-day rule for stool bacterial tests in Japan. Intern Med 2014; 53: 533-539.

  • Ishikawa H MM, Suzuki S, Tokudome S, Saida Y, Abe T, Okamura S, Tajika M, Joh T, Tanaka S, Kudo SE, Matsuda T, Iimuro M, Yukawa T, Takayama T, Sato Y, Lee K, Kitamura S, Mizuno M, Sano Y, Gondo N, Sugimoto K, Kusunoki M, Goto C, Matsuura N, Sakai T, Wakabayashi K. The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial. Gut. 2014; 63: 1755-1759.

  • Takeuchi Y IH, Tanaka S, Saito Y, Ikematsu H, Kudo SE, Sano Y, Hisabe T, Yahagi N, Saitoh Y, Igarashi M, Kobayashi K, Yamano H, Shimizu S, Tsuruta O, Inoue Y, Watanabe T, Nakamura H, Fujii T, Uedo N, Shimokawa T, Ishikawa H, Sugihara K. Factors associated with technical difficulties and adverse events of colorectal endoscopic submucosal dissection: retrospective exploratory factor analysis of a multicenter prospective cohort. Int J Colorectal Dis. 2014; 29: 1275-1284.

  • Kamada T HK, Ito M, Inoue K, Manabe N, Matsumoto H, Kusunoki H, Hata J, Yoshihara M, Sumii K, Akiyama T, Tanaka S, Shiotani A, David Y Graham. Time Trends in Helicobacter pylori Infection and Atrophic Gastritis Over 40 Years in Japan. Helicobacter. 2014.

  • Ishii Y, Sasaki T, Serikawa M, Kobayashi K, Kamigaki M, Minami T, Okazaki A, Yukitake M, Ishigaki T, Kosaka K, Mori T, Yoshimi S, Chayama K. Characteristic Features of Cholangiocarcinoma Complicating Primary Sclerosing. Cholangitis Hepato-Gastroenterology. 2014; 61, 567-573.

  • Ishitobi T, Hyogo H, Tokumo H, Arihiro K, Chayama K. Efficacy of probucol for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label pilot study. Hepatol Res. 2014; 44: 429-35.

  • Saibara T, Enomoto N, Kaneko S, Chayama K, Sata M, Imawari M, Onishi S, Okita K. Clinical efficacy of combination therapy with ME3738 and pegylated interferon-alpha-2a in patients with hepatitis C virus genotype 1. Hepatol Res. 2014; 44: 410-9.